Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticariaMarcus Maurer, Julian Storim, Vipul Jain et al.|Journal of Allergy and Clinical Immunology|2022Cited by 158
Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeksVipul Jain, Sibylle Haemmerle, Ana M. Giménez‐Arnau et al.|Journal of Allergy and Clinical Immunology|2023Cited by 71